[go: up one dir, main page]

AU7859900A - Compositions and methods for wt1 specific immunotherapy - Google Patents

Compositions and methods for wt1 specific immunotherapy

Info

Publication number
AU7859900A
AU7859900A AU78599/00A AU7859900A AU7859900A AU 7859900 A AU7859900 A AU 7859900A AU 78599/00 A AU78599/00 A AU 78599/00A AU 7859900 A AU7859900 A AU 7859900A AU 7859900 A AU7859900 A AU 7859900A
Authority
AU
Australia
Prior art keywords
compositions
methods
specific immunotherapy
immunotherapy
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU78599/00A
Inventor
Martin A Cheever
Steven G. Reed
Yasir A.W. Skeiky
Jiangchun Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corixa Corp
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of AU7859900A publication Critical patent/AU7859900A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU78599/00A 1999-10-04 2000-10-04 Compositions and methods for wt1 specific immunotherapy Abandoned AU7859900A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15745999P 1999-10-04 1999-10-04
US60157459 1999-10-04
PCT/US2000/027465 WO2001025273A2 (en) 1999-10-04 2000-10-04 Compositions and methods for wt1 specific immunotherapy

Publications (1)

Publication Number Publication Date
AU7859900A true AU7859900A (en) 2001-05-10

Family

ID=22563814

Family Applications (1)

Application Number Title Priority Date Filing Date
AU78599/00A Abandoned AU7859900A (en) 1999-10-04 2000-10-04 Compositions and methods for wt1 specific immunotherapy

Country Status (2)

Country Link
AU (1) AU7859900A (en)
WO (1) WO2001025273A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030185830A1 (en) * 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7008765B1 (en) 1997-04-10 2006-03-07 The Johns Hopkins University PCA3, PCA3 genes, and methods of use
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
CA2385477C (en) 1999-09-29 2009-11-03 Diagnocure Inc. Pca3 messenger rna species in benign and malignant prostate tissues
US20020048777A1 (en) 1999-12-06 2002-04-25 Shujath Ali Method of diagnosing monitoring, staging, imaging and treating prostate cancer
US6897024B2 (en) 2001-05-31 2005-05-24 Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen Nucleic acid molecules comprising the promoter for PCA3, and uses thereof
WO2003002142A1 (en) * 2001-06-29 2003-01-09 Chugai Seiyaku Kabushiki Kaisha Cancer vaccine containing cancer antigen based on tumor suppressor gene wt1 product and cationic liposomes
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
JP2006501166A (en) * 2002-06-11 2006-01-12 グラクソスミスクライン　バイオロジカルズ　ソシエテ　アノニム Immunogenic composition comprising heterologous prostate protein P501S
AU2003267254A1 (en) * 2002-09-20 2004-04-08 Dendreon Corporation Immunotherapeutic compositions and methods for the treatment of moderately to well-differentiated cancers
US20050282170A1 (en) 2003-02-07 2005-12-22 Diagnocure Inc. Method to detect prostate cancer in a sample
ATE462003T1 (en) 2004-03-31 2010-04-15 Int Inst Cancer Immunology Inc CANCER ANTIGEN PEPTIDES DERIVED FROM WT1
CA2491067A1 (en) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
WO2007047764A2 (en) 2005-10-17 2007-04-26 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
ES2587980T3 (en) 2006-02-22 2016-10-28 International Institute Of Cancer Immunology, Inc WT1 peptide with HLA-A * 3303 restriction and pharmaceutical composition containing it
WO2007120673A2 (en) 2006-04-10 2007-10-25 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and methods of use thereof
AU2012227350C1 (en) * 2006-12-28 2015-11-12 International Institute Of Cancer Immunology, Inc. HLA-A*1101-Restricted WT1 peptide and pharmaceutical composition comprising the same
CA2886619A1 (en) 2006-12-28 2008-07-10 International Institute Of Cancer Immunology, Inc. Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
JPWO2009066462A1 (en) * 2007-11-20 2011-04-07 日本電気株式会社 Cytotoxic T cell induction method, cytotoxic T cell inducer, and pharmaceutical composition and vaccine using the same
AR076349A1 (en) 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc CANCER ANTIGEN AUXILIARY PEPTIDE
US20150104413A1 (en) 2012-01-13 2015-04-16 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
PL2945647T3 (en) 2013-01-15 2021-03-08 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
RU2687026C2 (en) * 2013-02-05 2019-05-06 Нитто Денко Корпорейшн Vaccine composition against malignant tumor based on peptide wt1 for mucosal introduction
US11033613B2 (en) 2015-11-20 2021-06-15 Memorial Sloan Kettering Cancer Center Methods and compositions for treating cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622835A (en) * 1994-04-28 1997-04-22 The Wistar Institute Of Anatomy & Biology WT1 monoclonal antibodies
CN102198266A (en) * 1998-07-31 2011-09-28 株式会社国际癌症免疫研究所 Cancer antigens based on tumor suppressor gene WT1 product
KR100752065B1 (en) * 1998-09-30 2007-08-28 코릭사 코포레이션 VT1-specific immunotherapy compositions and methods

Also Published As

Publication number Publication date
WO2001025273A3 (en) 2002-07-11
WO2001025273A9 (en) 2003-01-30
WO2001025273A2 (en) 2001-04-12

Similar Documents

Publication Publication Date Title
AU7859900A (en) Compositions and methods for wt1 specific immunotherapy
PL348595A1 (en) Compositions and methods for wt1 specific immunotherapy
AUPQ419099A0 (en) Novel compositions and methods
AU2625501A (en) Compositions and methods for gene silencing
AU4133701A (en) Methods and compositions for peptide synthesis
AU5326100A (en) Pharmaceutical compositions and methods for use
AU3913800A (en) Novel antioxidant formulations and methods for using them
AU3864900A (en) Compositions and methods for their preparation from (lepidium)
AU5565099A (en) Pharmaceutical compositions and methods for use
AU2100901A (en) Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation
AUPP968699A0 (en) Therapeutic compositions and method for their preparation
AU2243797A (en) Methods and compositions for inhibiting hexokinase
AU7474100A (en) Methods and compositions for reducing immune response
AU1152601A (en) Compositions and their use
AU2681500A (en) Rapidly-soluble compositions
AU2002366809A1 (en) Syn3 compositions and methods
AU6094200A (en) Nor gene compositions and methods for use thereof
AU4779400A (en) Hair-treatment composition
AU6299800A (en) Turbocharger
AU3883800A (en) Hob-bp2h compositions, methods and uses thereof
AU5085300A (en) Compositions
AU1597001A (en) Compositions and methods for modifying an immune response against tropomyosin
AU6381000A (en) Methods and compositions for alleviating stuttering
AU4709900A (en) Hmx compositions and processes for their preparation
AU1601801A (en) Methods of preparing crna

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase